Ann: Response to ASIC Decision, page-57

I don't understand why shareholders are drawing comparisons with different companies, the truth of the matter is:

• Hct made claims that the virus was tested against covid19, it was not
• Hct made expected revenue announcements of 3.8 million which were 3 months later revised to 0.5 million
• Hct breached it's continuous disclosure

frankly this is a dog stock by proxy of it's management, a lot of people here (me included), were sold by the product and opportunity and were severely mislead

I lost roughly ~5k of which I've made back in excess on other stocks and which was within my risk tolerance. I know others here are in much deeper.

the truth of the matter is given how the company has dicked itself this is not an attractive investment opportunity to the market.

i suggest it's best to sit on the sidelines till actual (and ideally audited) revenue figures are released.

if this really is the amazing product it is made out to be then getting in a little later is definitely worth not taking on such huge levels of risk.

i think I've said enough on this stock now so since I'm not holding I'll refrain from posting anymore